1文献来源Sehn LH, Herrera AF, Flowers CR,et al.Polatuzumab Vedotin in relapsed or refractory diffuselarge B-cell lymphoma[J]. J Clin Oncol,2020,38(2):155-165.2 证据水平2a。3背景虽然弥漫大B细胞淋巴瘤(diffuse large B ce...1文献来源Sehn LH, Herrera AF, Flowers CR,et al.Polatuzumab Vedotin in relapsed or refractory diffuselarge B-cell lymphoma[J]. J Clin Oncol,2020,38(2):155-165.2 证据水平2a。3背景虽然弥漫大B细胞淋巴瘤(diffuse large B celllymphoma,DLBCL)患者经标准R-CHOP方案治疗可获得治愈,但仍有30%~40%的患者出现复发或者难治。展开更多
1文献来源Younes A,Sehn L H,Johnson P,et al. Randomized phase Ⅲ trial of Ibrutinib and Rituximab plus Cyclophosphamide,Doxorubicin,Vincristine,and Prednisone in non-germinal center B-cell diffuse large B-cell lymphoma...1文献来源Younes A,Sehn L H,Johnson P,et al. Randomized phase Ⅲ trial of Ibrutinib and Rituximab plus Cyclophosphamide,Doxorubicin,Vincristine,and Prednisone in non-germinal center B-cell diffuse large B-cell lymphoma[J]. J Clin Oncol,2019,37(15):1285-1295.2证据水平1b。3背景弥漫大B细胞淋巴瘤(diffuse large B-celllymphoma,DLBCL)是最为常见的一种淋巴瘤。展开更多
文摘1文献来源Sehn LH, Herrera AF, Flowers CR,et al.Polatuzumab Vedotin in relapsed or refractory diffuselarge B-cell lymphoma[J]. J Clin Oncol,2020,38(2):155-165.2 证据水平2a。3背景虽然弥漫大B细胞淋巴瘤(diffuse large B celllymphoma,DLBCL)患者经标准R-CHOP方案治疗可获得治愈,但仍有30%~40%的患者出现复发或者难治。
文摘1文献来源Younes A,Sehn L H,Johnson P,et al. Randomized phase Ⅲ trial of Ibrutinib and Rituximab plus Cyclophosphamide,Doxorubicin,Vincristine,and Prednisone in non-germinal center B-cell diffuse large B-cell lymphoma[J]. J Clin Oncol,2019,37(15):1285-1295.2证据水平1b。3背景弥漫大B细胞淋巴瘤(diffuse large B-celllymphoma,DLBCL)是最为常见的一种淋巴瘤。